Organic cation transporters are determinants of oxaliplatin cytotoxicity.

Although the platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin have similar DNA-binding properties, only oxaliplatin is active against colorectal tumors. The mechanisms for this tumor specificity of platinum-based compounds are poorly understood but could be related to differences in uptake. This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. The cytotoxicity of oxaliplatin was greater than that of cisplatin in six colon cancer cell lines [mean +/- SE of IC(50) in the six cell lines, 3.9 +/- 1.4 micromol/L (oxaliplatin) versus 11 +/- 2.0 micromol/L (cisplatin)] but was reduced by an OCT inhibitor, cimetidine, to a level similar to, or even lower than that of, cisplatin (29 +/- 11 micromol/L for oxaliplatin versus 19 +/- 4.3 micromol/L for cisplatin). Structure-activity studies indicated that organic functionalities on nonleaving groups coordinated to platinum are critical for selective uptake by OCTs. These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity. They also strongly suggest that expression of OCTs in tumors should be investigated as markers for selecting specific platinum-based therapies in individual patients. The development of new anticancer drugs, specifically targeted to OCTs, represents a novel strategy for targeted drug therapy. The results of the present structure-activity studies indicate specific tactics for realizing this goal.

[1]  N. Farrell,et al.  Synthesis and characterization of diastereomeric (substituted iminodiacetato)(1,2-diaminocyclohexane)platinum(II) complexes , 1988 .

[2]  C. Giandomenico,et al.  Current Status of Platinum-Based Antitumor Drugs , 1999 .

[3]  Heinz Bönisch,et al.  Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 , 2002, British journal of pharmacology.

[4]  J. Turchi,et al.  Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. , 1999, Biochemistry.

[5]  H. Koepsell,et al.  Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. , 2002, Molecular pharmacology.

[6]  D. Barlow,et al.  Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. , 1999, Genomics.

[7]  S. Masuda,et al.  Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. , 2005, Biochemical pharmacology.

[8]  A. Schinkel,et al.  Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[9]  S. Lippard,et al.  2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. , 2001, Inorganic chemistry.

[10]  R. Riccardi,et al.  Cellular and molecular aspects of drugs of the future: oxaliplatin , 2002, Cellular and Molecular Life Sciences CMLS.

[11]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[12]  C. Wagner,et al.  Platinum(II) and palladium(II) complexes analogous to oxaliplatin with different cyclohexyldicarboxylate isomeric anions and their in vitro antitumour activity. Structural elucidation of [Pt(C2O4)(cis-dach)] , 2003 .

[13]  D. Lebwohl,et al.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.

[14]  C. Giandomenico,et al.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. , 1995, Inorganic chemistry.

[15]  Conrad C. Huang,et al.  Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. , 2002, Pharmacogenetics.

[16]  C. Napier,et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.

[17]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[18]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[19]  S. Lippard,et al.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.

[20]  G. Samimi,et al.  The Copper Influx Transporter Human Copper Transport Protein 1 Regulates the Uptake of Cisplatin in Human Ovarian Carcinoma Cells , 2004, Molecular Pharmacology.

[21]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[22]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[23]  K. Giacomini,et al.  Cloning and functional expression of a human liver organic cation transporter. , 1997, Molecular pharmacology.

[24]  G. Rappold,et al.  Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter , 1998, Nature Neuroscience.

[25]  Z. Siddik,et al.  Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. , 2004, Molecular cancer therapeutics.

[26]  B. Rosenberg,et al.  Syntheses, kinetics, and mechanism of formation of polynuclear hydroxo-bridged complexes of (trans-1,2-diaminocyclohexane)platinum(II) , 1982 .

[27]  R. Goldberg,et al.  Systemic therapy for metastatic colorectal cancer: current options, current evidence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Howell,et al.  Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.

[29]  K. Inagaki,et al.  Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. , 1978, Journal of medicinal chemistry.

[30]  S. Chaney,et al.  Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. , 2005, Critical reviews in oncology/hematology.

[31]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[32]  R. Neubert,et al.  Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.

[33]  S. Chaney,et al.  Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. , 1990, Biochemistry.

[34]  G. Samimi,et al.  Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells , 2004, Clinical Cancer Research.

[35]  S. Lippard,et al.  Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.

[36]  T. Ludwig,et al.  Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. , 2005, The American journal of pathology.

[37]  A. Eastman,et al.  Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. , 1989, Chemico-biological interactions.

[38]  B. Desoize,et al.  Particular aspects of platinum compounds used at present in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[39]  William C Reinhold,et al.  Membrane Transporters and Channels , 2004, Cancer Research.

[40]  J. Kaski,et al.  Cardiac syndrome X: an overview. , 2000, Hospital practice.

[41]  F. Lang,et al.  Cloning and characterization of two human polyspecific organic cation transporters. , 1997, DNA and cell biology.

[42]  R. Weiss,et al.  New Cisplatin Analogues in Development A Review , 2022 .

[43]  S. Wright.  Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. , 2005, Toxicology and applied pharmacology.

[44]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Raymond,et al.  Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[47]  J. Misset,et al.  Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.